Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Global Companion Diagnostics Market to Reach a New Threshold of Growth: Expected to Reach USD 7.8 Billion in 2027

Published

on

Noida, India, June 24, 2021 (GLOBE NEWSWIRE) — A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the global companion diagnostics market reached USD 3.6 billion in 2020 and is further projected to reach USD 7.8 billion by 2027, growing at a CAGR of 10.8% during 2021-2027 (forecast period). The global companion diagnostics market has been witnessing healthy growth potential owing to the rising prevalence of cancer cases around the world. The vigorous growth of the global companion diagnostics market can also be attributed to various factors influencing the global healthcare scenario, such as rising clinical trials on patients, growing emphasis on personalized medicines, and the surge in demand for next-generation sequencing, among others.

Request for free Sample of the report: Click Here

The growing demand for customized medicines is driving the global companion diagnostics market growth

The global companion diagnostics market is experiencing substantial growth owing to a surge in demand for customized medicines. Companion diagnostics have proven useful in various evidence-based laboratory analyses and clinical evaluations, thereby providing more information for the healthcare professionals in crafting more precisely tailored medicines with higher efficacies. For instance, in September 2020, Roche, a research-focused healthcare company with capabilities ranging from diagnostics to pharmaceuticals had developed a SARS-CoV-2 antibody test that helps generate accurate and quicker results than the expected duration. The advent of such advanced technologies, combined with highly effective diagnostic tests, is contributing to the growth of the companion diagnostics market, globally.

The escalating number of clinical trials bolstering the global companion diagnostics market growth

To obtain approval for the commercial end-use of any medicine, the drug is required to pass through all of the four phases of clinical trials that are known for being time-consuming and challenging. However, the companion diagnostics agent can help you identify disease-specific biomarkers and assist in recruiting patients based on the demand for the trials. Clinical trials have started becoming a cost-effective affair owing to the surge in usage of companion diagnostics in the field of medication development and customized medicines.

According to the U.S. National Library of Medicine, the registered studies of clinical trials were recorded to be at around 381,053 as of JuneUnew June 2021 2021. The historical trend suggests that the clinical trials are increasing at a faster pace as the statistic recorded in 2020 stands at 325,793 against 293,274 in the year 2019. The record growth of the clinical trials in the U.S. alone indicates that the clinical trials and studies will continue to grow even in the foreseeable future. As a result, the rising number of clinical trials has been augmenting the growth of the global companion diagnostics market.

The PCR segment occupies the largest market share in the global companion diagnostics market

Based on technology, the global companion diagnostics market can be segmented into PCR, ISH, NGS, and IHC, and others. The Polymerase Chain Reaction (PCR) sub-segment accounted for the largest share under the technology segment. The world is confronting a lot of challenges owing to the pandemic that has claimed the lives of around 4 million people. The RT-PCR (Reverse Transcription Polymerase Chain Reaction) kit is the only way off identifying COVID-19 infection with higher effectiveness and precision. The PCR tests have a low allele frequency of genes, and high turnaround time in comparison to other technologies for which they are in huge demand. The promptness and high-reliability rate of PCR tests is positively contributing to the growth of the global companion diagnostics market.

The cancer sub-segment accounted for the largest share in the indication segment of the global companion diagnostics market

Based on indication, the global companion diagnostics market is segmented into cardiovascular, neurological diseases, cancer, infectious diseases, and others. The cancer segment held the largest share in the global companion diagnostics market in 2020 and is expected to witness strong growth over the forecast period as well. According to the WHO, cancer is the second leading cause of death worldwide, following cardiovascular illnesses, claiming more than 10 million lives in 2020 alone. The most prevalent cancer types diagnosed in 2020 are as follows—breast (2.24 million cases), lung (2.20 million cases), colon and rectum (1.92 million cases), prostate (1.40 million cases), skin (1.19 million cases), and stomach (1.08 million cases). Among these cases, the largest number of deaths were documented in the lung cancer category, which recorded nearly 1.80 million deaths in the year 2020 alone. 

The data cited above emphasizes the importance of proper diagnosis in diseases with higher mortality rates. Cancerous diseases are often treated with the help of oncology treatment as it is an effective approach to detect cancerous cells in the human body. Oncology treatment has been witnessing an upward trend owing to the1 rising investment opportunities for research and development around the world. The rising number of cancer patients has only augmented the demand for such treatments which are positively impacting the global companion diagnostics market.

North America to Remain Prolific in the Global Companion Diagnostics Market

The global companion diagnostics market is divided into North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America. The North American region accounted for the largest share in the global companion diagnostics industry in 2020. The region is equipped with advanced healthcare facilities and has a presence of a large number of pharmaceutical and biotech companies that have been contributing to the escalation of the global companion diagnostics market. Furthermore, North America is one of the most cancer-affected regions in the world, and the number is predicted to worsen in the approaching years as the geriatric population increases, thereby contributing to the growth of the global companion diagnostics market.

Europe holds the second position in terms of revenue in the global companion diagnostics market. Europe is witnessing healthy growth as a result of its highly efficient healthcare workforce and systems. Furthermore, increasing awareness of the necessity of adopting precise diagnostic instruments, electronic health records, and drugs prescribed precisely for a disease promotes the growth of the market in the region. Europe also spends a lot of money on healthcare. They also have public and private sector investment for R&D, as well as a well-developed healthcare industry in the region, which is propelling the growth of the global companion diagnostics market.

Enquire before purchase: Click here

COVID-19 Impact Analysis

The COVID-19 outbreak as well as the government-induced lockdown restrictions have had a negative impact on the global companion diagnostics market. Because of the nationwide lockdown imposed by the governments of different countries, the supply chain confronted disruptions, and availability concerns mounted amid a rising number of COVID-19 cases. However, the discretion offered to the healthcare domain amid the COVID-19 pandemic has helped the global companion diagnostics market to witness a growth potential as they continued offering their testing services to various healthcare professionals around the world. Companion diagnostics testing kits have also made it possible to determine the safety and efficacy rates of COVID-19 vaccines and medicines for cancer patients undergoing therapy. As a result, following a period of sluggish growth, the companion diagnostics market is expected to witness immense growth potential in the coming years.

Healthy Competition Driving Market Outcomes

The leading players in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Abbott Laboratories, Almac Group (U.K.), Danaher Corporation (U.S.), Illumina, bioMérieux SA (France), Myriad Genetics, Sysmex Corporation (Japan), Thermo Fisher Scientific, Abnova Corporation (Taiwan), and other prominent players. The large presence of new companies has resulted in healthier competition among long-established service providers in the industry, thereby providing more opportunities for new entrants in the global companion diagnostics market.

In March 2021, Agilent Technologies Inc. announced that the company has acquired Resolution Bioscience Inc. The acquisition is expected to complement and augment Agilent’s strength in NGS-based cancer diagnostics, thereby providing more room for innovative technologies to serve the demands of the fast-growing precision medicine market. Agilent Technologies Inc. is expected to pay USD 550 million in cash and an additional sum of USD 145 million on the basis of future performance milestones. Resolution Bioscience’s non-invasive biopsy assay platform is supported by the clinical oncology diagnostic testing market as well as the biopharma services market. The platform is designed for a centralized Clinical Laboratory Improvement Amendments (CLIA) test service that comes in the form of a distributable kit.

In May 2021, QIAGEN N.V. announced the launch of an extended form of companion diagnostic claims for the therascreen KRAS Kit after receiving U.S. regulatory approval. As a companion diagnostic served in aiding and identifying non-small cell lung cancer (NSCLC) patients, it is making them eligible for receiving treatment under LUMAKRASTM, which is the latest approved therapy marketed and developed by Amgen Inc. The new approval is expected to further help the market leader in strengthening and expanding its therascreen portfolio of companion diagnostic tests. It also demonstrates the company’s commitment to assisting in the timely delivery of most recent innovations in precision healthcare to patients suffering from NSCLC cancer.

Scope of Report

By Product

  • Assay kits & Reagents
  • Software & Services

By Technology 

  • PCR
  • ISH
  • NGS
  • IHC
  • Others

By End-Users

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • CROs
  • Others

By Indication

  • Cardiovascular
  • Neurological Diseases
  • Cancer
  • Infectious Diseases
  • Others

By Region

  • North America
  • Europe
  • The Asia-Pacific
  • Latin America
  • The Middle East & Africa

Other similar reports:

Global Companion Animal Diagnostics Market, By Technology (Clinical Biochemistry, Molecular Diagnostics, Immunodiagnostics, Urinalysis, Hematology, and Other), By Animal Type (Dogs, Cats, Horses, and Others), By Application (Bacteriology, Parasitology, Virology, Clinical Pathology, Others), By End-User (Diagnostic Laboratories, Veterinary Hospitals & Clinics, Research Institutes & Universities), , By Region (North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle-East & Africa (MEA) Trend Analysis, Competitive Market Share & Forecast, 2017-2027

Global Diagnostic Catheter Market, By Product Type (Cardiovascular Catheters, Neurovascular Catheters, Urological Catheters, Specialty Catheters, Intravenous Catheters, Other Types), By Application (Gastroenterology, Cardiology, Urology, Neurology, Others), By End-User (Hospitals, Imaging & Diagnostic Centers), By Region (North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle-East & Africa (MEA) Trend Analysis, Competitive Market Share & Forecast, 2017-2027

Global Artificial Intelligence Diagnostic Market Size, By Solution (Hardware and Software & Services), By Technology (Speech Recognition, Querying Method, Natural Language Processing, Machine Learning, and Context-Aware Processing), By Application (Imaging & Diagnostics, Drug Discovery, Lifestyle Management & Monitoring, Emergency Room & Hospital Management, Insights & Risk Analytics, Wearables, Virtual Assistants, and Others), By End User (Hospitals, Pharmaceutical Organizations, Diagnostic Centers, and Clinics), By Region (North America, Europe, Asia Pacific, South America, and the Middle East & Africa), Trend Analysis, Market Competition Scenario & Outlook, 2017-2027

Global Cancer Diagnostics Market, by Application (Imaging, Tumor Biomarkers Tests, Biopsy, Immunohistochemistry, Liquid Biopsy, In Situ Hybridization), by Type(Endometrial Cancer, Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Kidney Cancer, Leukemia, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer, Liver-Lung Cancer, Melanoma, Non-Hodgkin Lymphoma), by End-User(Diagnostic Laboratories, Hospitals, Diagnostic Imaging Centers, Cancer Research Institutes. and Documentation System), by Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Global Opportunity Analysis and Industry Forecast, 2017–2027

Global Diagnostic Medical Imaging Market, By Product Type (Computed Tomography (CT) Scanners, X-ray Imaging Systems, MRI Systems, Ultrasound Imaging Systems, Nuclear Imaging Systems and Mammography Systems), By Application (Neuronal Spine, Orthopedics and Musculoskeletal, Cardiovascular and Thoracic and General Imaging), By End-user (Hospitals and Imaging Centers); By Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2017-2027

More reports on Healthcare & Pharmaceutical: Click Here

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer all-inclusive market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solutions. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.


Artificial Intelligence

Transmission Electron Microscope Market Projected to Reach $3.92 billion by 2030 – Exclusive Report by 360iResearch

Published

on

transmission-electron-microscope-market-projected-to-reach-$3.92-billion-by-2030-–-exclusive-report-by-360iresearch

PUNE, India, March 27, 2024 /PRNewswire/ — The report titled “Transmission Electron Microscope Market by Mode (Bright Field, Dark Field), Type (Aberration corrected TEM, Cryo-TEM, Environmental/In-situ TEM), Product Type, Application, End Users – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $2.05 billion in 2023 to reach $3.92 billion by 2030, at a CAGR of 9.71% over the forecast period. 

“The Rising Importance of Transmission Electron Microscopes in Global Research and Development”
Transmission electron microscopy (TEM) is a pivotal analytical tool across various scientific disciplines, including nanotechnology, materials science, and biology. This advanced technology operates by channeling a high-energy beam of electrons through ultra-thin samples, rendering images that unveil structures at the atomic level. The increasing investments in research and development, coupled with the growing demand for intricate analysis in sectors such as electronics, semiconductors, and healthcare, have significantly amplified the need for TEM. Challenges include high costs, the necessity for specialized training, and complex sample preparation. Advancements are underway, including integrating AI and ML to address these hurdles. Regionally, the Americas, particularly the U.S. and Canada, are at the forefront of TEM adoption, owing to their robust investment in cutting-edge research fields. The APAC region, led by China, Japan, and India, is making swift advances, supported by governmental research funding and a keen focus on innovation. Europe’s strong R&D ecosystem, supported by governmental and EU funding, further complements the global outreach of TEM technology. The role of TEM in nanoworld is increasingly indispensable, highlighting its significance in propelling scientific and technological advancements globally.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/transmission-electron-microscope
“Revolutionizing Semiconductor Production with Advanced Imaging; the Critical Role of Transmission Electron Microscopy”
In the rapidly advancing world of semiconductor manufacturing, the advent of transmission electron microscopy (TEM) marks a transformative step in producing and inspecting semiconductor devices. As the industry moves toward creating devices with finer details on the nanometer scale, the unparalleled resolution of TEM emerges as a vital tool. This advanced imaging technique provides an in-depth analysis of semiconductor materials, revealing critical insights into their structure and composition at an atomic level. TEM is essential in refining the manufacturing process, ensuring devices are high-performing and reliable by precisely identifying minuscule defects and material inconsistencies. Its ability to visualize the smallest details of device architecture assists in inspecting each manufacturing stage, preventing potential structural failures. The integration of TEM into the semiconductor manufacturing process highlights a commitment to excellence, paving the way for innovations that meet the growing demands for more powerful and efficient electronic devices. Through its contribution to material science and fabrication, TEM ensures the industry’s stride toward miniaturization and complexity in semiconductor devices remains steady and informed.
“The Power of Dark Field TEM in Unveiling Microscopic Defects”
Bright-field transmission electron microscopy (TEM) stands out for its ability to produce high-contrast images that reveal the intricate structures and dimensions of materials at the nano level, making it an indispensable tool for understanding the morphology of biological specimens, thin films, and nanoparticles. However, when investigating the hidden internal structures and defects of crystalline materials, Dark Field TEM emerges as a superior technique. Dark field TEM can visualize minute structural defects and dislocations that often go unnoticed, offering invaluable insights for materials science and engineering professionals. This method provides a detailed view of the material’s inner architecture, making it a go-to choice for those looking to delve deeper into the complexities of crystal structures and nanoparticles, contributing significantly to future advancements.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/transmission-electron-microscope
“Hitachi Ltd. at the Forefront of Transmission Electron Microscope Market with a Strong 15.12% Market Share”
The key players in the Transmission Electron Microscope Market include Thermo Fisher Scientific Inc., Carl Zeiss AG, AMETEK, Inc, Bruker Corporation, Hitachi Ltd., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Transmission Electron Microscope Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Transmission Electron Microscope Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Transmission Electron Microscope Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/transmission-electron-microscope
“Dive into the Transmission Electron Microscope Market Landscape: Explore 183 Pages of Insights, 574 Tables, and 26 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsTransmission Electron Microscope Market, by ModeTransmission Electron Microscope Market, by TypeTransmission Electron Microscope Market, by Product TypeTransmission Electron Microscope Market, by ApplicationTransmission Electron Microscope Market, by End UsersAmericas Transmission Electron Microscope MarketAsia-Pacific Transmission Electron Microscope MarketEurope, Middle East & Africa Transmission Electron Microscope MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/transmission-electron-microscope
Related Reports:
Electron Microscopy & Sample Preparation Market – Global Forecast 2024-2030Cryo-electron Microscopy Market – Global Forecast 2024-2030Scanning Electron Microscopes Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearch
Mr. Ketan Rohom 360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/transmission-electron-microscope-market-projected-to-reach-3-92-billion-by-2030—exclusive-report-by-360iresearch-302101136.html

Continue Reading

Artificial Intelligence

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Published

on

xtalpi-to-present-the-latest-progress-of-its-ai-cancer-vaccine-design-platform-at-aacr-2024

BEIJING and HONG KONG, March 28, 2024 /PRNewswire/ — XtalPi, a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, today announced it will present a poster showcasing the latest accomplishments of its AI-powered platform for designing cancer vaccines at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi’s poster will be included in the online Proceedings of the AACR.

“We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy. Together, we are committed to overcoming conventional limitations in creating new therapeutics and deploying cutting-edge technologies to benefit patients worldwide,” said Dr. Lipeng Lai, Co-founder and Chief Innovation Officer at XtalPi.
POSTER PRESENTATION DETAILS
Abstract 3525: Towards the efficient design of shared neoantigen peptide cancer vaccines using artificial intelligence
Authors: Genwei Zhang, Jiewen Du, Xiangrui Gao, Tianyuan Wang, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Ruohan Zhu, Yalong Zhao, Samson Li, Melvin Toh, Lipeng Lai
Session Date and Time: Monday, April 8(th), 1:30 PM – 5:00 PM Pacific Standard Time
The accurate prediction of immunogenicity of cancer vaccines remains elusive. We developed new models that predict the probability of a given peptide derived from the protein of interest to be presented by MHC-I or MHC-II.
For MHC-I antigen presentation model development, over 17 million entries in the dataset were collected from published literature and available databases, such as IEDB, with peptide lengths ranging from 8 to 11. The peptides were restricted to 150 unique MHC-I alleles. Similarly, ~4 million entries with peptide lengths ranging from 13 to 21 were collected for MHC-II antigen presentation model development, and the peptides were restricted to 19 unique MHC-II alleles. To develop advanced antigen presentation models, a language model was chosen as the backbone network, and contrastive learning was used to better discriminate the peptide-MHC match versus mismatch. Overall, both MHC-I and MHC-II presentation models were constructed with about 30 million parameters.
To validate algorithm prediction accuracy and peptide immunogenicity, 28 predicted patentable peptides derived from mutated TP53 protein were synthesized and their binding to respective common HLA alleles was validated using surface plasmon resonance. We found that over 80% of the peptides displayed binding affinities stronger than the positive control, suggesting that AI significantly improves the design of neoantigen peptide vaccines. Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
DETAILS ON XTALPI PEPTIDE R&D PLATFORM
XtalPi Innovation Center based in Beijing has established a fully integrated peptide R&D platform that combines dry-lab design with wet-lab validation and optimization to advance the rapid development of peptides for nutraceuticals, cosmetics, and pharmaceuticals.
The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides. It is also equipped for automated synthesis, automated cleavage, and purification of peptides, as well as high-resolution mass spectrometry analysis and sequence identification.
In addition, XtalPi has established high-throughput one-bead-one-compound (OBOC)-based screening workflows for peptide and mRNA-encoded peptide libraries, which provide one-pot molecule screening of millions and trillions of molecules respectively. Its library screening enables rapid identification and improvement of peptide candidates’ affinities. The seamless integration of dry and wet lab capabilities significantly shortens the peptide discovery and optimization cycles, leading to a higher experimental success rate.
About XtalPi
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Logo – https://mma.prnewswire.com/media/2374018/4619419/XtalPi_EN_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-to-present-the-latest-progress-of-its-ai-cancer-vaccine-design-platform-at-aacr-2024-302101880.html

Continue Reading

Artificial Intelligence

Major shift in global IPO market share from the past five years

Published

on

major-shift-in-global-ipo-market-share-from-the-past-five-years

Q1 2024 global IPO volumes fell 7%, but proceeds were up 7% YOYThe US picked up after a 20-year low in proceeds in 2022AI is experiencing significant growth in private domainLONDON, March 28, 2024 /PRNewswire/ — The year kicked off on a cautiously optimistic note, marked by a selective thaw following a quieter period. The Americas and EMEIA IPO markets had a bright start in 2024, increasing global proceeds. However, the Asia-Pacific region started on a weak note, weighing down the overall global volume. For Q1 2024, the global IPO market saw 287 deals raise US$23.7b, a 7% decrease but a 7% increase year-over-year (YOY), respectively. These and other findings are available in the EY Global IPO Trends Q1 2024.

In Q1 2024, a majority of key IPO markets witnessed a significant number of newly issued IPOs whose current share prices surpassed their offer prices. This trend could indicate an improvement in valuations and pricing levels, reflecting growing confidence among issuers and investors.
An IPO is one of the pinnacle achievements for private equity (PE) firms, serving as a public showcase of their acumen and a defining milestone in their growth journey. In Q1 2024, approximately 10 PE-backed IPOs came to the market, five of which were featured among the top 10 global IPOs, a testament to their significant market presence.
The promise and reach of the artificial intelligence (AI) vertical is currently experiencing significant growth within the private realm, with the majority of AI and AI-associated businesses still in the seed or early stage of venture capital (VC) rounds. This suggests there could be a surge in IPOs in future years as these companies mature in the private domain before making a public debut.
Overall regional performance: Americas and EMEIA recovering and Asia-Pacific plunging
The global IPO market has experienced significant shifts in geographical composition, driven by ongoing macroeconomic and geopolitical dynamics.
The Americas continued to exhibit strong performance in IPO activity compared with both the previous quarter and Q1 2023, with 52 deals and US$8.4b in proceeds, up 21% and up a whopping 178%, respectively, YOY. Each of the top seven deals in Q1 2024 raised over US$500m, versus just one in Q1 2023. The US, after experiencing a 20-year low in proceeds in 2022, has finally witnessed a noticeable recovery in the first quarter of the year, riding on the wave of the market rally from last year.
Driven by a subdued IPO market sentiment across the region, Asia-Pacific IPO activity in Q1 recorded 119 deals and US$5.8b in proceeds, down 34% and 56% YOY, respectively. This decline was especially sharp in Mainland China and Hong Kong, with the number of deals decreasing more than half and deal size falling by nearly two-thirds. Both markets have experienced a consistent decline in IPO activity over the past few years. There have been only 10 IPOs so far this year in Hong Kong, with two exceeding US$100m in deal size, marking a historic low since 2010 by proceeds. Japan was the only market in Asia-Pacific to see a slight increase in deal count in the first quarter, with the Nikkei Index hitting an all-time high in February.
The EMEIA IPO market witnessed an impressive growth at the start of the year, launching 116 IPOs totaling US$9.5b in the first quarter, up 40% and 58% YOY, respectively. This surge was attributed to larger average deal sizes from IPOs in Europe and India, which enabled EMEIA to maintain first place in global IPO market share by proceeds since Q4 2023. Since 2019, India has rapidly gained prominence, particularly in the number of IPOs, and has now emerged as a standout performer.
Q2 2024 outlook: capitalizing on fleeting windows amid heightened uncertainties
George Chan, EY Global IPO Leader, says:
“As 2024 unfolds, participants in the IPO market are entering uncharted territory. IPO candidates are influenced by the recent pivot in investors’ preference toward proven profitability in an altered interest rate landscape, and are doing this while facing the intricate dynamics of an intensified geopolitical climate and the buzz around AI. To succeed in this shifting environment, IPO prospects must remain flexible and prepared to seize the right moment for their public debuts.”
The IPO market thus far in 2024 has shown signs of vigor, with an upswing in IPO activity. Despite the restrained overall market activity in previous years, there’s an uptick in enthusiasm from both IPO issuers and investors, hinting at shifting market dynamics and a more welcoming landscape for public listings.
The global economy will remain on a soft growth trajectory in 2024, with developed markets likely to see modest growth while emerging markets stay on a firmer growth path. Stock markets have already priced in the expectation of rate cuts in various major economies.
Just as investors and IPO candidates adapt to the new norm of higher interest rates and reduced liquidity, they will also need to navigate through additional layers of complexity in the geopolitical and global election landscape in the IPO market. As elections this year amplify uncertainty, IPO candidates will need to closely monitor election outcomes and assess how specific policies could affect stakeholder interests and re-evaluate IPO strategies and timing as necessary. 
Notes to editors
About EY
EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.
Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.
Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today. 
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com. 
This news release has been issued by EYGM Limited, a member of the global EY organization that also does not provide any services to clients. 
About EY Private
As Advisors to the ambitious™, EY Private professionals possess the experience and passion to support private businesses and their owners in unlocking the full potential of their ambitions. EY Private teams offer distinct insights born from the long EY history of working with business owners and entrepreneurs. These teams support the full spectrum of private enterprises including private capital managers and investors and the portfolio businesses they fund, business owners, family businesses, family offices and entrepreneurs. Visit ey.com/private.
About EY IPO services
Going public is a transformative milestone in an organization’s journey. As the industry-leading advisor in initial public offering (IPO) services, EY teams advise ambitious organizations around the world and helps equip them for IPO success. EY teams serve as trusted business advisors guiding companies from start to completion, strategically positioning businesses to help achieve their goals over short windows of opportunity and preparing companies for their next chapter in the public eye. ey.com/ipo
About the data
The data presented here is available on ey.com/ipo/trends. Q1 2024 refers to the first quarter of 2024 and covers completed IPOs from 1 January to 18 March 2024, plus expected IPOs by 31 March 2024 (forecasted as of 18 March 2024). All data contained in this document is sourced from Dealogic, Mergermarket, Pitchbook, Capital IQ and EY analysis unless otherwise noted. The Dealogic data in this report are under license by ION. ION retains and reserves all rights in such data. SPAC data are excluded from all data in this report, except where indicated.
Lauren MoseryEY Global Media Relations+1 732 977 [email protected]
Logo- https://mma.prnewswire.com/media/381362/EY_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/major-shift-in-global-ipo-market-share-from-the-past-five-years-302101659.html

Continue Reading

Trending